The $10M raise buys runway but at significant dilution (~6.4% of shares outstanding) for a pre-revenue company with no near-term catalyst. The company explicitly states Phase 3 requires partnership or additional financing — this offering may be a bridge, not a solution. Monitor for partnership announcements or further capital needs; the stock may face continued pressure from the dilutive overhang and the placement agent warrants (exercisable at $5.00, above the $4.00 offering price).
Price Chart
Executive Summary
CervoMed priced a $10M registered direct offering of 2.5M shares at $4.00/share (at-the-market under Nasdaq rules), expected to close June 22, 2026. Net proceeds will fund working capital and general corporate purposes. The company also issued placement agent warrants exercisable at $5.00/share, representing 6% of the offering shares. This dilutive capital raise comes as CervoMed is a clinical-stage biotech with no approved products and a $39M market cap — the offering represents ~26% of pre-deal market cap.
Key Financial Metrics
Key Facts
- 2,500,000 shares sold at $4.00/share for $10M gross proceeds
- Offering priced at-the-market under Nasdaq rules; no premium
- Placement agent warrants issued for 150,000 shares (6% of offering) at $5.00/share exercise price
- Net proceeds for working capital and general corporate purposes
- Company is pre-revenue clinical-stage biotech with $39M market cap
- 30-day lock-up on further equity issuances; 6-month ban on variable rate transactions
- Phase 3 trial in DLB requires partnership and/or additional financing — no partner yet
Financial Impact
Dilution of approximately 6.4% based on 39M market cap and $4.00 price; $10M gross proceeds represent ~26% of pre-deal market cap
Risk Factors
- Dilution of ~6.4% from the offering; additional dilution from placement agent warrants
- No approved products; clinical-stage risk with Phase 3 dependent on partnership/financing
- Cash runway may be insufficient to reach Phase 3 data without additional capital
- Stock price at $4.00 is near the $5.00 warrant exercise price — warrants may never be exercised, but overhang remains
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-021208 |
| Exhibit: ex_978642.htm | 0001437749-26-021208 |
| Exhibit: ex_978643.htm | 0001437749-26-021208 |
| Exhibit: ex_978641.htm | 0001437749-26-021208 |
| Document: crvo20260618_8k.htm | 0001437749-26-021208 |
| Document: 0001437749-26-021208-index-headers.html | 0001437749-26-021208 |
| Document: 0001437749-26-021208-index.html | 0001437749-26-021208 |
| Document: 0001437749-26-021208.txt | 0001437749-26-021208 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $2.25 $2.24 | ▼ −0.44% | ▲ +0.66% | $2.24 (−0.44%) |
Oct 13, 2026 13d ago | 8-K | $2.27 $2.29 | ▲ +0.88% | ▲ +1.96% | $2.24 (−1.32%) |
Oct 9, 2026 17d ago | 8-K | $2.51 $2.27 | ▼ −9.56% | ▼ −9.55% | $2.24 (−10.76%) |
Sep 10, 2026 6w ago | Press Release | $2.48 $2.57 | ▲ +3.63% | ▲ +2.78% | $2.24 (−9.68%) |
Aug 10, 2026 11w ago | 8-K | $3.09 $3.07 | ▼ −0.65% | ▼ −0.90% | $2.24 (−27.51%) |
Aug 4, 2026 11w ago | 8-K | $2.80 $2.81 | ▲ +0.36% | ▲ +0.56% | $2.24 (−20.00%) |
Aug 4, 2026 11w ago | Press Release | $2.80 $2.81 | ▲ +0.36% | ▲ +0.56% | $2.24 (−20.00%) |
Jul 13, 2026 15w ago | EFFECT | $3.31 $3.08 | ▲ +6.95% | ▲ +7.30% | $2.24 (+32.33%) |
Jul 6, 2026 16w ago | S-3 | $3.42 $3.41 | ▲ +0.29% | ▼ −0.02% | $2.24 (+34.50%) |
Jun 22, 2026 18w ago | 8-K | $3.72 $3.26 | ▲ +12.37% | ▲ +12.32% | $2.24 (+39.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers